Navigation Links
Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome
Date:1/15/2014

CAMBRIDGE, Mass., Jan. 15, 2014 /PRNewswire/ -- Zafgen, Inc., a leading biopharmaceutical company dedicated to addressing the unmet needs of severely obese patients, today announced initial results from its Phase 2a study of beloranib, a selective inhibitor of methionine aminopeptidase 2 (MetAP2), in patients with Prader-Willi syndrome (PWS), a severe form of genetic obesity.  These results showed improvements in body weight, hunger-related behaviors, and body composition, including reductions in body fat content and preserved lean body mass following four weeks of treatment. 

These changes were observed despite the increased caloric intake that was a component of this trial.  Known markers of beloranib response including those associated with cardiovascular disease risk were also improved, demonstrating that PWS patients responded to the molecular mechanism of beloranib.

"The results of this short-term proof-of-concept study are very promising and underscore our belief that beloranib has the potential to successfully treat this severe form of obesity.  To our knowledge, this study represents the largest placebo-controlled, randomized, multiple dose trial to date for obesity in this patient population, and these results bode well for further study of beloranib in patients with this devastating condition," said Thomas Hughes, Ph.D., President and Chief Executive Officer of Zafgen.

Similar to results seen in non-PWS obese patient populations, beloranib treatment in this study reduced body fat content by 8.1% vs. placebo in four weeks of treatment at the highest study dose of 1.8 mg, despite a 50% increased daily caloric allowance.  Hunger-related behaviors improved, and a trend towards overall improvement in body weight was seen, although this did not reach statistical significance, in part due to the fact that study was not powered to demonstrate these differ
'/>"/>

SOURCE Zafgen, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Zafgen Announces Initiation of Phase 2a Clinical Development with Beloranib in Obesity
2. Zafgen Secures $21 Million in Series D Financing
3. Zafgen Announces New Weight Loss and Safety Data from Phase 2 Study of Beloranib in Obesity at Obesity Week 2013
4. Zafgen Secures $45 Million in Series E Financing
5. Zafgen Appoints Chief Commercial Officer and New Member of Board of Directors
6. Precision Optics Corporation Announces $1 Million Order for Microprecision™ Based Endoscopes
7. Young Innovations, Inc. Announces Record Sales and EPS for the Quarter Ended March 31, 2012
8. JDRF Announces Research Collaboration with Dexcom, Inc. to Develop "Smart Transmitter" Technology to Accelerate Artificial Pancreas Studies
9. Misonix Announces New Distribution Agreement For Panama
10. University of Maryland BioPark Announces MedImmunes Dr. Bahija Jallal as Newest Member of Board of Directors for UM Health Sciences Research Park
11. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/31/2015)... March 31, 2015 /CNW/ - T-Bird Pharma Inc. (TSXV:TPI) ("T-Bird" ... premium quality medical marijuana products and a licensed producer ... Purposes Regulations ( Canada ) ("MMPR"), is ... The Corporation of the District of Saanich ... Company,s premises which now allows for commercial distribution of ...
(Date:3/31/2015)... -- Immune Pharmaceuticals Inc. ("Immune", the "Company") (NASDAQ: ... its planned bullous pemphigoid (BP) clinical development for bertilimumab, ... is an orphan auto-immune blistering disease of the skin ... Europe . As previously announced, ... II clinical trial in Israel ...
(Date:3/31/2015)... , March 31, 2015 ANI Pharmaceuticals, Inc. ... of Propafenone Hydrochloride 150mg, 225mg and 300mg oral tablets, ... The overall US market for Propafenone Hydrochloride 150mg, 225mg ... IMS Health. Arthur S. Przybyl , ... to announce the launch of our fourth product from ...
Breaking Medicine Technology:T-Bird Pharma Inc. Announces Final Municipal Rezoning Approval 2T-Bird Pharma Inc. Announces Final Municipal Rezoning Approval 3Immune Pharmaceuticals To Expand Bullous Pemphigoid Clinical Development Plan For Bertilimumab 2Immune Pharmaceuticals To Expand Bullous Pemphigoid Clinical Development Plan For Bertilimumab 3Immune Pharmaceuticals To Expand Bullous Pemphigoid Clinical Development Plan For Bertilimumab 4ANI Pharmaceuticals Announces the Launch of Propafenone Tablets 2ANI Pharmaceuticals Announces the Launch of Propafenone Tablets 3
... ROYAL OAK, Mich., March 4, 2011 Doctors ... minimally invasive robotic procedure to correct atrial fibrillation, ... new robotic maze procedure is an alternative to ... with fewer complications and a shorter hospital stay. ...
... March 4, 2011 The pressure for a new ... with organizations across the pharmaceutical sector facing pipeline deficits, ... Facing an ever-changing launch landscape, product launch leaders are ... therapies through the labyrinth of regulatory and marketplace challenges. ...
Cached Medicine Technology:Beaumont First in State to Perform Robotic Heart Procedure for Atrial Fibrillation 2Beaumont First in State to Perform Robotic Heart Procedure for Atrial Fibrillation 3Pharmaceutical Launch Excellence Services Delivers Market Entry Road Map 2
(Date:3/31/2015)... Illinois (PRWEB) March 31, 2015 ... Visio Stencils Device Library for documenting and diagramming ... following Visio Stencils: , Manufacturer / Device ... PowerEdge r720, Dell PowerEdge r520, Dell PowerEdge r630, ... Power 8 Series, EMC VMAX 100K, VMAX 200K, ...
(Date:3/31/2015)... Indiana (PRWEB) March 31, 2015 ... DeRose in Youngstown, Ohio in 1987. This ... the curve with not just customer satisfaction, but ... been added to the well-stocked arsenal of Yesco ... by American Green Technology® (AGT). The patented environmental ...
(Date:3/31/2015)... 31, 2015 Burns Engineering announces 3-Day Quick ... for the Food & Beverage, Pharmaceutical and Biotech markets. These ... ASME-BPE compliant and are now available as part of Burns’ ... , The S01 and S03 with 1/8” and ... process connections used in process lines 1/4” and larger. ...
(Date:3/31/2015)... 31, 2015 The Heart Fit ... Calgary and surrounding areas. External Counterpulsation is an ... artery disease, specifically stable coronary artery disease. ... is used extensively all over the world for ... Calgarians (Albertans) are extremely fortunate to have the ...
(Date:3/31/2015)... Orlando, FL (PRWEB) March 31, 2015 ... and Sickness Insurance programs, issues a travel advisory to ... Health care costs in the United States are higher ... than even in developed countries. For example, a ... while the same procedure costs about $34,358 . ...
Breaking Medicine News(10 mins):Health News:Altima Adds More Hardware Devices to its NetZoom™ Visio® Stencils Device Library 2Health News:American Green Technology® Signs Exclusive Agreement to Distribute Health Risk Management System in Midwest 2Health News:Burns Engineering Now Offers 3-Day Quick Ship on Sanitary RTDs and Thermocouples 2Health News:New Heart Disease Treatment Called External Counterpulsation (EECP) helps people of Alberta Who Have Failed or Are Not Suitable For Heart Stents or Surgery 2Health News:India Network Foundation issues travel advisory to all US bound travelers on visitor health insurance requirements 2Health News:India Network Foundation issues travel advisory to all US bound travelers on visitor health insurance requirements 3
... is in the process of doing away with a commonly ... phase out the ‘Aropax’ brand of paroxetine and bring in ... used by about 49,000 New Zealanders. ,This move ... maintains that both drugs are the same, except for the ...
... Forest University Baptist Medical Center are helping to lead ... that will test 3,000 patients in an effort to ... patients. ,Though doctors have promoted the value of ... training has not been definitively established as safe in ...
... why we shed tears. But exactly what our tears are made ... study sheds some light on the complex design of tears. What ... made up of three distinct, microscopic layers. The middle, watery layer ... – is sandwiched between a layer of mucus and an outer ...
... is an alarming rise of gambling and gamblers in Britain. ... gambling and casinos then on vegetables and fruits. ... been spent on gambling in United Kingdom. Online gambling has ... time. ,The British medical Association (BMA) has expressed ...
... The death of a 47-year-old man who had worked for ... hundreds of ex-employees, who had also been exposed to toxic ... Thursday, prompting more than 500 protestors, who said he had ... roads and demand an autopsy to assess the possibility of ...
... Plc, Europe's pharmaceutical giant, is finalizing its plan of action, ... Gardasil, in a bid to establish the most effective vaccine ... conducted in the United States, will seek to evaluate the ... to two strains of the human papillomavirus. This virus is ...
Cached Medicine News:Health News:New International Study to Test Exercise in Heart Failure Patients 2Health News:New International Study to Test Exercise in Heart Failure Patients 3Health News:Tears Reveal Some of Their Deepest Secrets to Researchers 2Health News:Tears Reveal Some of Their Deepest Secrets to Researchers 3Health News:Ex-workers Ask HLL to Accept Liability for Mercury Deaths 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: